Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | July 29, 2016 | July 29, 2016 |
| AbbVie Inc.ABBV · Entity 2800 | Director | May 08, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date July 29, 2016 · Filed July 29, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 395,819 |
Ending reported balance
After 2016-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-07-29 · Exercise / conversion · Acquired 56,000 · Balance 438,682 Row 2 · 2016-07-29 · Tax withholding · Disposed 42,863 · Balance 395,819 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.25 · Expires 2017-02-15 | Direct | 0 |
Reported balance
After 2016-07-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2016-07-29 · Exercise / conversion · Disposed 56,000 · Balance 0 F6: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,130 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,130 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of July 28, 2016. |
| Common shares without par valueSEC Table I · non-derivative | IndirectAnnette Newton-Freyman 1994 Trust | 4,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,000 F2: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectAnnette Newton-Freyman 2012 Irrevocable Trust | 76,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 76,000 F3: Held in the Annette Newton-Freyman 2012 Irrevocable Trust. The reporting person is trustee of the trust. The trust is irrevocable. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectThomas C. Freyman 2012 Irrevocable Trust | 76,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 76,000 F4: Held in the Thomas C. Freyman 2012 Irrevocable Trust. The reporting person's spouse is trustee of the trust. The trust is irrevocable. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy spouse as trustee for son | 1,941 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 1,941 F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy spouse as trustee for son | 1,941 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,941 F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of July 28, 2016.
F2: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
F3: Held in the Annette Newton-Freyman 2012 Irrevocable Trust. The reporting person is trustee of the trust. The trust is irrevocable. The reporting person disclaims beneficial ownership of these securities.
F4: Held in the Thomas C. Freyman 2012 Irrevocable Trust. The reporting person's spouse is trustee of the trust. The trust is irrevocable.
F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities.
F6: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
AbbVie Inc.
Report date May 08, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 127,869 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 1,118 · Balance 127,869 F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust | 4,000 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,000 F2: The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust for son | 1,941 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,941 F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust for son | 1,941 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,941 F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allergan plc
Report date May 08, 2020 · Filed May 12, 2020
Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-08 · Disposition to issuer · Disposed 2,983 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
HANGER, INC.
Report date October 03, 2022 · Filed October 04, 2022
Section 16 reporting ended · disclosed 2022-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 43,561 · Balance 0 F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash.
TENNECO INC
Report date November 17, 2022 · Filed November 21, 2022
Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-17 transaction · row 1
1 source rowRow 1 · 2022-11-17 · Disposition to issuer · Disposed 93,892 · Balance 0 F1: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub, upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub, upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2010 Filed Feb 3, 2010 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $53.39 | $106,780.00 |
DisclosureSEC source: 0001179110-10-001963 · edgar.xml · nonDerivative · entry 9 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,715 Read SEC document |
| February 01, 2010 Filed Feb 3, 2010 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $53.38 | $101,422.00 |
DisclosureSEC source: 0001179110-10-001963 · edgar.xml · nonDerivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,715 Read SEC document |
| February 01, 2010 Filed Feb 3, 2010 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,600 | $53.37 | $85,392.00 |
DisclosureSEC source: 0001179110-10-001963 · edgar.xml · nonDerivative · entry 7 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,615 Read SEC document |
| February 01, 2010 Filed Feb 3, 2010 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,300 | $53.35 | $229,405.00 |
DisclosureSEC source: 0001179110-10-001963 · edgar.xml · nonDerivative · entry 5 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,715 Read SEC document |
| February 01, 2010 Filed Feb 3, 2010 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,000 | $53.34 | $213,360.00 |
DisclosureSEC source: 0001179110-10-001963 · edgar.xml · nonDerivative · entry 4 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,015 Read SEC document |
| February 01, 2010 Filed Feb 3, 2010 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,000 | $53.33 | $266,650.00 |
DisclosureSEC source: 0001179110-10-001963 · edgar.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,015 Read SEC document |
| February 01, 2010 Filed Feb 3, 2010 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,700 | $53.32 | $197,284.00 |
DisclosureSEC source: 0001179110-10-001963 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,015 Read SEC document |
| February 01, 2010 Filed Feb 3, 2010 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $53.31 | $42,648.00 |
DisclosureSEC source: 0001179110-10-001963 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,715 Read SEC document |
| November 11, 2009 Filed Nov 13, 2009 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 20,000 | $53.50 | $1,070,000.00 |
DisclosureSEC source: 0001179110-09-015476 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,515 Read SEC document |
| February 27, 2009 Filed Mar 3, 2009 16:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,760 | $50.58 | $392,500.80 |
DisclosureSEC source: 0001104659-09-013729 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,515 Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 108,200 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011812 · a4.xml · derivative · entry 6 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,200 Underlying: Common shares · 108,200 shares Expires 2019-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,067 on 2/20/2010, 36,067 on 2/20/2011 and 36,066 on 2/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 76,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011812 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,275 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 254 | $54.41 | $13,820.65 |
DisclosureSEC source: 0001104659-09-010773 · a4.xml · nonDerivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,075 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $54.41 | $10,882.80 |
DisclosureSEC source: 0001104659-09-010773 · a4.xml · nonDerivative · entry 7 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,329 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.41 | $5,441.28 |
DisclosureSEC source: 0001104659-09-010773 · a4.xml · nonDerivative · entry 6 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,529 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.41 | $5,441.23 |
DisclosureSEC source: 0001104659-09-010773 · a4.xml · nonDerivative · entry 5 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,629 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.41 | $5,441.22 |
DisclosureSEC source: 0001104659-09-010773 · a4.xml · nonDerivative · entry 4 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,729 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.41 | $5,441.21 |
DisclosureSEC source: 0001104659-09-010773 · a4.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,829 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.41 | $5,441.00 |
DisclosureSEC source: 0001104659-09-010773 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,929 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,808 | $54.94 | $154,271.52 |
DisclosureSEC source: 0001104659-09-010773 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,029 Read SEC document |
| February 04, 2009 Filed Feb 6, 2009 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value · Derivative | 20,882 | $0.00 Strike: $52.55 | $0.00 |
DisclosureSEC source: 0001104659-09-007371 · a4.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 20,882 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 04, 2009 Filed Feb 6, 2009 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 19,778 | $56.98 | $1,126,950.44 |
DisclosureSEC source: 0001104659-09-007371 · a4.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,837 Read SEC document |
| February 04, 2009 Filed Feb 6, 2009 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 20,882 | $52.55 | $1,097,349.10 |
DisclosureSEC source: 0001104659-09-007371 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2009 Filed Feb 6, 2009 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 370 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-007371 · a4.xml · nonDerivative · entry 7 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By self for son Disclosed balance after: 1,567 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his daughter and sons. Read SEC document |
| January 26, 2009 Filed Feb 6, 2009 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 370 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-007371 · a4.xml · nonDerivative · entry 6 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By self for son Disclosed balance after: 1,567 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his daughter and sons. Read SEC document |
| January 26, 2009 Filed Feb 6, 2009 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 370 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-007371 · a4.xml · nonDerivative · entry 5 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 1,567 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his daughter and sons. Read SEC document |
| January 26, 2009 Filed Feb 6, 2009 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-007371 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,733 Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value · Derivative | 27,848 | $0.00 Strike: $53.19 | $0.00 |
DisclosureSEC source: 0001104659-08-047211 · a4.xml · derivative · entry 7 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 27,848 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 26,563 | $57.58 | $1,529,497.54 |
DisclosureSEC source: 0001104659-08-047211 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,426 Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 27,848 | $53.19 | $1,481,235.12 |
DisclosureSEC source: 0001104659-08-047211 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2008 Filed Mar 5, 2008 01:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,630 | $54.22 | $196,818.60 |
DisclosureSEC source: 0001104659-08-015210 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,141 Read SEC document |
| February 18, 2008 Filed Feb 20, 2008 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,223 | $55.55 | $67,937.65 |
DisclosureSEC source: 0001104659-08-011833 · a4.xml · nonDerivative · entry 4 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,771 Read SEC document |
| February 17, 2008 Filed Feb 20, 2008 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,761 | $55.55 | $208,923.55 |
DisclosureSEC source: 0001104659-08-011833 · a4.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,994 Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 127,500 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011833 · a4.xml · derivative · entry 9 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Underlying: common shares · 127,500 shares Expires 2018-02-14 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 42,500 on 2/15/09, 42,500 on 2/15/10 and 42,500 on 2/15/11. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 31,400 | $55.56 | $1,744,584.00 |
DisclosureSEC source: 0001104659-08-011833 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,755 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 11, 2008 Filed Feb 20, 2008 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 352 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-08-011833 · a4.xml · nonDerivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By self for son Disclosed balance after: 1,197 F3 · ownership.nature: The reporting person disclaims beneficial ownership of all securities held by his daughter and sons. Read SEC document |
| February 11, 2008 Filed Feb 20, 2008 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 352 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-08-011833 · a4.xml · nonDerivative · entry 7 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By self for son Disclosed balance after: 1,197 F3 · ownership.nature: The reporting person disclaims beneficial ownership of all securities held by his daughter and sons. Read SEC document |
| February 11, 2008 Filed Feb 20, 2008 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 352 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-08-011833 · a4.xml · nonDerivative · entry 6 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 1,197 F3 · ownership.nature: The reporting person disclaims beneficial ownership of all securities held by his daughter and sons. Read SEC document |
| February 11, 2008 Filed Feb 20, 2008 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 1,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-08-011833 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,355 Read SEC document |
| February 05, 2008 Filed Feb 8, 2008 01:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value · Derivative | 2,012 | $0.00 Strike: $54.62 | $0.00 |
DisclosureSEC source: 0001104659-08-008184 · a4.xml · derivative · entry 7 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,012 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 05, 2008 Filed Feb 8, 2008 01:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,936 | $58.05 | $112,384.80 |
DisclosureSEC source: 0001104659-08-008184 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,411 Read SEC document |
| February 05, 2008 Filed Feb 8, 2008 01:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,012 | $54.62 | $109,895.44 |
DisclosureSEC source: 0001104659-08-008184 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 25,602 | $0.00 Strike: $58.90 | $0.00 |
DisclosureSEC source: 0001104659-07-088510 · a4.xml · derivative · entry 11 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,602 Underlying: common shares · 25,602 shares Expires 2013-02-13 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 10,318 | $0.00 Strike: $58.90 | $0.00 |
DisclosureSEC source: 0001104659-07-088510 · a4.xml · derivative · entry 10 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,318 Underlying: common shares · 10,318 shares Expires 2010-02-10 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 29,290 | $0.00 Strike: $46.65 | $0.00 |
DisclosureSEC source: 0001104659-07-088510 · a4.xml · derivative · entry 9 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 29,290 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 11,767 | $0.00 Strike: $46.92 | $0.00 |
DisclosureSEC source: 0001104659-07-088510 · a4.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 11,767 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 35,920 | $58.90 | $2,115,688.00 |
DisclosureSEC source: 0001104659-07-088510 · a4.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,335 Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 29,290 | $46.65 | $1,366,378.50 |
DisclosureSEC source: 0001104659-07-088510 · a4.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2007 Filed Dec 12, 2007 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 11,767 | $46.92 | $552,102.93 |
DisclosureSEC source: 0001104659-07-088510 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2007 Filed Dec 4, 2007 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 56,835 | $0.00 Strike: $57.00 | $0.00 |
DisclosureSEC source: 0001104659-07-086861 · a4.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,835 Underlying: common shares · 56,835 shares Expires 2011-02-08 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.